March 3, 2026

Trial design and enrolment characteristics of LATA (long-acting treatment in adolescents): A randomised, open-label, non-inferiority, 96-week trial evaluating the virological efficacy, safety, acceptability and quality-of-life of the dual long-acting injectable regimen cabotegravir/ rilpivirine compared to daily oral therapy in virologically suppressed adolescents with HIV-1 infection, aged 12 to <20 years, in Sub-Saharan Africa

Virological efficacy is comparable between the long-acting injectable regimen and daily oral therapy.
Participants aged 12 to <20 years were enrolled over 96 weeks to assess various outcomes.
Randomised, open-label trial design assesses acceptability and quality-of-life along with safety metrics.
Potential implications for HIV treatment strategies in adolescents, emphasizing the need for external validation.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Anena et al. (Wed,) studied this question.

Diana Anena

Elizabeth Chappell

Rashidah Nazzinda

Building similarity graph...

Analyzing shared references across papers